Development of σ-receptor ligands and clinical trials

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

There are at least two classes of σ-receptors, termed σ1 and σ2. Recently, the σ1-receptor has been completely sequenced in different species. The amino acid sequences of the different purified proteins are highly homologous, but it shares no homology to know mammalian proteins. These results suggest that the σ1 receptor is a distinct entity from any often known receptors, σ-Receptors are involved in many physiological functions. Therefore, σ-ligands show many different pharmacological effects such as glucose utilization, neuroprotective, antipsychotic, antidepressive, anxiolytic, nootropic, antiepileptic, antiabuse, antitussive, antidiarrhea, anti-inflammatory, tear protein releasing stimulant and central anti- micturition reflex actions. These results suggest that σ-receptors are very promising targets for the development of new drugs that have new mechanisms of action.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalFolia Pharmacologica Japonica
Volume114
Issue number1
Publication statusPublished - 27-07-1999
Externally publishedYes

Fingerprint

Clinical Trials
Central Nervous System Stimulants
Antitussive Agents
Nootropic Agents
Ligands
Urination
Anti-Anxiety Agents
Anticonvulsants
Antipsychotic Agents
Reflex
Amino Acid Sequence
Proteins
Anti-Inflammatory Agents
Pharmacology
Glucose
Pharmaceutical Preparations
tear proteins

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{a4210128b7cf4c4eb4ab92925a55ee40,
title = "Development of σ-receptor ligands and clinical trials",
abstract = "There are at least two classes of σ-receptors, termed σ1 and σ2. Recently, the σ1-receptor has been completely sequenced in different species. The amino acid sequences of the different purified proteins are highly homologous, but it shares no homology to know mammalian proteins. These results suggest that the σ1 receptor is a distinct entity from any often known receptors, σ-Receptors are involved in many physiological functions. Therefore, σ-ligands show many different pharmacological effects such as glucose utilization, neuroprotective, antipsychotic, antidepressive, anxiolytic, nootropic, antiepileptic, antiabuse, antitussive, antidiarrhea, anti-inflammatory, tear protein releasing stimulant and central anti- micturition reflex actions. These results suggest that σ-receptors are very promising targets for the development of new drugs that have new mechanisms of action.",
author = "Toshitaka Nabeshima and I. Muraoka",
year = "1999",
month = "7",
day = "27",
language = "English",
volume = "114",
pages = "3--11",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "1",

}

Development of σ-receptor ligands and clinical trials. / Nabeshima, Toshitaka; Muraoka, I.

In: Folia Pharmacologica Japonica, Vol. 114, No. 1, 27.07.1999, p. 3-11.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Development of σ-receptor ligands and clinical trials

AU - Nabeshima, Toshitaka

AU - Muraoka, I.

PY - 1999/7/27

Y1 - 1999/7/27

N2 - There are at least two classes of σ-receptors, termed σ1 and σ2. Recently, the σ1-receptor has been completely sequenced in different species. The amino acid sequences of the different purified proteins are highly homologous, but it shares no homology to know mammalian proteins. These results suggest that the σ1 receptor is a distinct entity from any often known receptors, σ-Receptors are involved in many physiological functions. Therefore, σ-ligands show many different pharmacological effects such as glucose utilization, neuroprotective, antipsychotic, antidepressive, anxiolytic, nootropic, antiepileptic, antiabuse, antitussive, antidiarrhea, anti-inflammatory, tear protein releasing stimulant and central anti- micturition reflex actions. These results suggest that σ-receptors are very promising targets for the development of new drugs that have new mechanisms of action.

AB - There are at least two classes of σ-receptors, termed σ1 and σ2. Recently, the σ1-receptor has been completely sequenced in different species. The amino acid sequences of the different purified proteins are highly homologous, but it shares no homology to know mammalian proteins. These results suggest that the σ1 receptor is a distinct entity from any often known receptors, σ-Receptors are involved in many physiological functions. Therefore, σ-ligands show many different pharmacological effects such as glucose utilization, neuroprotective, antipsychotic, antidepressive, anxiolytic, nootropic, antiepileptic, antiabuse, antitussive, antidiarrhea, anti-inflammatory, tear protein releasing stimulant and central anti- micturition reflex actions. These results suggest that σ-receptors are very promising targets for the development of new drugs that have new mechanisms of action.

UR - http://www.scopus.com/inward/record.url?scp=0032778430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032778430&partnerID=8YFLogxK

M3 - Review article

C2 - 10562960

AN - SCOPUS:0032778430

VL - 114

SP - 3

EP - 11

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 1

ER -